A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma

Inclusion Criteria: 1. Age:18 to 70 years old (man or female); 2. Pathologically diagnosed with esophageal squamous cell carcinoma; 3. Patients with Stage for Ⅱ-Ⅲ(T2-4N0/+M0) (According to transesophageal ultrasonography; 4. Patients with measurable lesions(According to the criteria in RECIST1.1); 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; 6. Life expectancy greater than or equal to 3 months; 7. Major organ function has to meet the following certeria: (1) For results of blood routine test 1. HB≥80g/L; 2. ANC≥1.5×109/L; 3. PLT≥90×109/L; (2) For results of blood biochemical test a) ALT and AST≤2.5×ULN; b) TBIL\<1.5×ULN; c) Serum creatinine ≤1.5×ULN; 8. Doctors believe that treatment can bring benefits to patients; 9. Participants were willing to join in this study, and written informed consent, good adherence, cooperate with the follow-up. Exclusion Criteria: 1. Have received prior treatment with chemotherapy or radiotherapy； 2. Have high blood pressure and antihypertensive drug treatment can not control; 3. Patients with severe cardiovascular disease ; 4. Accompanied by esophageal perforation and esophagotracheal fistula; 5. Patients with active bleeding or bleeding tendency; 6. Pregnant or lactating women; 7. The researchers think inappropriate.